Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer (CemiHALT )

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT04243616

Title field or adapter rule

{'original_value': 'Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer (CemiHALT )', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:30.504307+00:00

Published At

2026-07-27T00:00:00+00:00

Record Updated At

2026-10-20

Results Posted At

2026-07-27

Source Retrieved At

2026-10-31T22:18:22.973355+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Invasive Breast Cancer"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-20", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT04243616"

protocolSection.identificationModule.officialTitle

"Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer (CemiHALT )"

protocolSection.statusModule.overallStatus

"ACTIVE_NOT_RECRUITING"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

{"date": "2026-07-27", "type": "ACTUAL"}

Study condition terms

• Invasive Breast Cancer (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Drug Treatment'], 'description': '350 mg, IV, Day 1 of Cycle 1-2 (3-week cycle)', 'name': 'Cemiplimab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Drug Treatment'], 'description': '80 mg/m\\^2, IV, Day 1,8 and 15 of Cycles 1-4 (3-week cycle)', 'name': 'Paclitaxel', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Drug Treatment'], 'description': 'Area under curve (AUC)=6, IV, Day 1 of Cycles 1-4 of Paclitaxel cycles (3-week cycle)', 'name': 'Carboplatin (not mandatory)', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Drug Treatment'], 'description': '60 g/m\\^2, IV, Day 1 of Cycles 1-4 of ddAC (2-week cycle)', 'name': 'Doxorubicin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Drug Treatment'], 'description': '600 g/m\\^2, IV, Day 1 of Cycles 1-4 of dose-dense Adriamycin (Doxorubicin) and Cyclophosphamide (ddAC) (2-week cycle)', 'name': 'Cyclophosphamide', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Cemiplimab (protocolSection.armsInterventionsModule.interventions[].name)
• Paclitaxel (protocolSection.armsInterventionsModule.interventions[].name)
• Carboplatin (not mandatory) (protocolSection.armsInterventionsModule.interventions[].name)
• Doxorubicin (protocolSection.armsInterventionsModule.interventions[].name)
• Cyclophosphamide (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.